利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

321 条记录 (耗时 0.018 秒)

    INFUSION SOLUTION FOR PERIPHERAL INTRAVENOUS ADMINISTRATION
    36.
    发明公开
    INFUSION SOLUTION FOR PERIPHERAL INTRAVENOUS ADMINISTRATION 审中-公开
    INFUSIONSLÖSUNGZUR PERIPHERENINTRAVENÖSENVERABREICHUNG

    公开(公告)号：EP2163249A1

    公开(公告)日：2010-03-17

    申请号：EP08764571.9

    申请日：2008-05-23

    申请人： Ajinomoto Co., Inc.

    发明人： SHIGETA, Mutsuo ,  ABIKO, Kazuhiro

    IPC分类号： A61K31/7004 ,  A61K9/08 ,  A61K31/19 ,  A61K31/191 ,  A61K31/198 ,  A61K31/51 ,  A61K47/02 ,  A61K47/12 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61P3/02

    CPC分类号： A61K9/0019 ,  A61K31/19 ,  A61K31/191 ,  A61K31/198 ,  A61K31/51 ,  A61K31/7004 ,  A61K47/02 ,  A61K47/26

    摘要： There is provided an infusion solution for peripheral intravenous administration comprising a multichamber vessel constructed in a connectable manner, which separately houses a sugar solution containing sugars, electrolytes and vitamin B1, and an amino acid solution containing amino acids, electrolytes and a sulfite, whereby the vitamin B1 and amino acids are stably maintained.
    In the infusion solution for peripheral intravenous administration, the sugar solution contains calcium gluconate, contains no greater than 1.4 g/L sodium lactate, has a pH of 4.0-4.7 and has a titratable acidity of 2-4, the amino acid solution contains 4.0-8.0 g/L sodium lactate, contains no calcium gluconate, has a pH of 6.8-7.2, contains free L-cysteine as cysteine and contains 0.05-0.2 g/L sodium hydrogen sulfite, and after the sugar solution and amino acid solution have been mixed, the infusion solution has a pH of 6.5-7.1 and a titratable acidity of 5-10.

    摘要翻译： 提供了一种用于外周静脉内施用的输注溶液，其包括以可连接的方式构建的多室容器，其分开容纳含有糖，电解质和维生素B1的糖溶液以及含有氨基酸，电解质和亚硫酸盐的氨基酸溶液，由此 维生素B1和氨基酸稳定保持。 在用于外周静脉内给药的输液中，糖溶液含有葡萄糖酸钙，含有不大于1.4g / L乳酸钠，pH值为4.0-4.7，滴定酸度为2-4，氨基酸溶液含有4.0 -8.0 g / L乳酸钠，不含葡萄糖酸钙，pH值为6.8-7.2，含有游离L-半胱氨酸作为半胱氨酸，含有0.05-0.2 g / L亚硫酸氢钠，糖溶液和氨基酸溶液后 输液溶液的pH值为6.5-7.1，滴定酸度为5-10。

    STABILE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN VON 5,10-METHYLENTETRAHYDROFOLAT
    37.
    发明授权
    STABILE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN VON 5,10-METHYLENTETRAHYDROFOLAT 有权
    5,10-亚甲基稳定的药物组合物

    公开(公告)号：EP1641460B1

    公开(公告)日：2009-08-19

    申请号：EP04763030.6

    申请日：2004-06-28

    申请人： Merck Eprova AG

    发明人： MOSER, Rudolf ,  AMMANN, Thomas

    IPC分类号： A61K31/519 ,  A61K31/191 ,  A61P35/00

    CPC分类号： A61K47/12 ,  A61K31/00 ,  A61K31/191 ,  A61K31/505 ,  A61K31/519 ,  A61K47/08

    摘要： The invention relates to 5,10-methylene-(6R)-,-(6S)-or (6R,S)-tetrahydrofolate (MTHF) pharmaceutical compounds whose stability is due to the adjustment thereof to a basic pH value and to a simultaneous citrate use. Said stabilisation is self-producible in the absence of a reducing agent. Said invention is particularly suitable for preparing lyophilization solution or lyophilisates or dry powders and dry mixtures since the stable MTHF solutions can be filled at the high concentration thereof into corresponding recipients like, for example vials, ampoules etc. Said lyophilisates are surpassingly storable and stable. They are easily reconstituted by adding water or aqueous solutions, thereby providing diluted injection solutions ready for use with an excellent stability. Said invention also makes it possible to produce highly concentrated calcium or acid MTHF salts, even difficult-to-dissolve, in the form of isotonic physiologically compatible solutions.